2004年博士毕业于美国肯塔基大学。博士毕业后进入哈佛大学医学院从事为期两年的博士后工作。2006年7月加入哈佛大学＆麻省理工学院博德研究院工作任研究员II, 于2013年晋升为研究员II并工作至2020年9月，期间自2018年7月到2020年6月脱产参加由美国医学遗传学专家委员会和俄克拉荷马大学医学院联合举办的执业专家培训。

     Dr. Hongcang Gu obtained his Ph.D degree from University of Kentucky in 2004. After that, he went to Harvard Medical School and joined the laboratory of Professor Thomas L. Benjamin as a post-doctoral scholar. In July 2006, Dr. Gu moved to the newly established Broad Institute of Harvard and MIT and worked as research scientist I, and was promoted to a Research Scientist II position in 2013. Dr. Gu completed the Laboratory Genetics and Genomics (LGG) training program jointed offered by American Board of Medical Genetics and Genomics (ABMGG) and University of Oklahoma Health Sciences Center in July 2020. While working at Broad Institute, Dr. Gu developed multiple next-generation sequencing (NGS) based technologies, such as Reduced Representation Bisulfite sequencing (RRBS), whole genome bisulfite sequencing (WGBS), ChIP-bisulfite-sequencing (ChIP-BS-seq), and Smart-RRBS for jointly profiling the methylome and transcriptome of the same single cell. Dr. Gu is a productive scientist and has published 60 papers in top journals including Nature, Cell, Nature Methods, Nature Genetics, and Nature Protocols. His publications have been cited more 20,000 times as of June 2021.

     高通量基因测序技术，表观遗传学，肿瘤发生、发展及演化的机理

博士招生计划：           1、专业：生物物理学招生方向：null           2、专业：计算机应用技术招生方向：null 学术硕士招生计划：           1、专业：计算机应用技术（硕士）招生方向：不区分研究所和研究方向           1、专业：计算机科学与技术（安大联培）招生方向：null           2、专业：生物学（安大联培）招生方向：null 博士招生计划：           1、专业：计算机应用技术招生方向：生物信息学 学术硕士招生计划：           1、专业：生物物理学（硕士）招生方向：肿瘤生物学

迄今发表论文六十多篇，近四十篇发表在 Nature， Cell 及其子刊。论文他引二万多次。申请人最早将高通量基因测序计术引入表现遗传学领域，最先发表以二代测序技术为基础的简化甲基化测序技术，全基因组甲基化测序技术，免疫共沉淀甲基化测序技术及单细胞甲基化和转录组共测序技术。目前这些技术在表观遗传学，发育生物学和干细胞领域得到广泛的应用。 通过对人不同组织及细胞全基因甲基化测序，首次详细阐明了 DNA 甲基化修饰的基本情况及人体不同细胞组织之间甲基化修饰动态变化的规律，发现了 DNA 甲基化修饰与组蛋白修饰之间的内在关系，并且进一步发现转录因子与 DNA 甲基化修饰之间的内在联系，探明了 DNA 甲基化修饰与单核苷酸多态性之间的因果关系(Ziller, Gu et al., Nature, 2013)。

代表性论文: 1. Gaiti F*, Chaligne R*, Gu H*, Brand RM, Hill SK, Schulman R, Grigorev K , Risso D, Kim K, Pastore A, Huang KY, Alonso A, Omans ND, Biederstedt E, Clement K, Wang L, Felsenfeld JA, Bhavsar EB, Aryee M, Allan JN, Furman R, Gnirke A, Wu CJ, Meissner A and Dan A. Landau DA. (2019) Epigenetic evolution and lineage histories of chronic lymphocytic leukemia. Nature, 569, 576–580. 2. Gu H, Bock C, Mikkelsen TS, Jäger N, Smith ZD, Tomazou E, Gnirke A, Lander ES, Meissner A. (2010) Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nature Methods, 7(2):133-6. 3. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. (2011) Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nature Protocol, 6(4):468-81. 4. Boyle P*, Clement K*, Gu H*, Smith ZD, Ziller M, Fostel JL, Holmes L, Meldrim J, Kelley F, Gnirke A. Meissner A. (2012) Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biology, 13(10):R92. 5. Gu H, Raman A, Wang X, Smith ZD, Mohammad AM, Aryee M. Gnirke A, Meissner M. (2021) Analyzing the methylome and transcriptome of a single cell at once. Nature Protocols (Accepted). 6. Pang, H, Yu X, Kim YM, Wang X, Jinkins JK, Yin Y, Li S, Gu H. (2020) Disorders Associated With Diverse, Recurrent Deletions and Duplications at 1q21. 1. Frontiers in Genetics 11, 577-581. 7. Ziller MJ, Gu H, Donaghey J, Elkabetz Y, Bernstein BE, Gnirke A and Meissner A. (2013) The dynamic DNA methylation landscape of the human genome. Nature, 500: 477-481. 8. Tsankov AM, Gu H, Akopian V, Ziller MJ, Donaghey J, Amit I, Gnirke A, Meissner A. (2015) Transcription factor binding dynamics during human ES cell differentiation. Nature, 518(7539):344-9. 9. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES. (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature, 454(7205):766-70. 10. Smith ZD, Shi J, Gu H, Dongahey J, Cacciarelli D, Gnirke A, Michor F, and Meissner A. (2017) Epigenetic restriction of embryonic and extraembryonic lineages mirrors the somatic transition to cancer. Nature, 549(7673):543-547. 11. Liao J, Karnik R, Gu H, Ziller MJ, Clement K, Tsankov AM, Akopian V, Gifford CA, Donaghey J, Galonska C, Pop R, Reyon D, Tsai SQ, Mallard W, Joung JK, Rinn JL, Gnirke A, Meissner A. (2015) Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nature Genetics, 47(5):469-78. 12. Gifford CA, Ziller MJ, Gu H, Trapnell C, Donaghey J, Tsankov A, Shalek AK, Kelley DR, Shishkin AA, Issner R, Zhang X, Coyne M, Fostel JL, Holmes L, Meldrim J, Guttman M, Epstein C, Park H, Kohlbacher O, Rinn J, Gnirke A, Lander ES, Bernstein BE, Meissner A. (2013) Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell, 23;153(5):1149-63 13. Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, Marks H, Bock C, Gnirke A, Meissner A, Stunnenberg HG.(2012) Sequential ChIP-bisulfite sequencing enables direct genome- scale investigation of chromatin and DNA methylation cross-talk. Genome Research, 22(6):1128-38. 14. Gu H, Li D, Sung CK, Yim H, Troke P, Benjamin T. (2011) DNA-binding and regulatory properties of the transcription factor and putative tumor suppressor p150(Sal2). Biochim Biophys Acta, 1809(4- 6):276-83.